bioAffinity Technologies, Inc. - An Investor’s Plain-English Guide

Thinking about investing in bioAffinity Technologies? It is exciting to look at new biotech companies, but you need to cut through the technical jargon to see what is happening under the hood. Here is the breakdown in plain English.

1. What does this company actually do?

Think of bioAffinity as a detective for lung health. They created a test called CyPath® Lung. Instead of a risky biopsy where a doctor cuts out tissue, their test checks a patient’s phlegm sample. They use a special chemical that makes cancer cells glow under a microscope, making them much easier to spot. Their goal is to make early cancer detection safer and more accurate.

The company earns money through its subsidiary, Precision Pathology Laboratory Services (PPLS), which provides lab testing. While CyPath® Lung is their main product, they are still in the early stages of commercialization. Currently, their sales are not high enough to cover their operating costs.

2. What is happening with their stock right now?

This is not a company growing through massive sales. Instead, they rely on "private placements." These are deals where they sell stock and "warrants"—coupons to buy more stock later—to private investors to keep the company running.

Why does this matter to you?

• The "Coupon" Effect: The company issued a massive number of warrants over the last two years. In August 2024, they issued warrants to buy over 8 million shares at $0.352 each. Every time these coupons are used, the company creates new shares. This results in more shares issued, which dilutes your ownership percentage of the company.
• Price Adjustments: The company frequently lowers the price at which these investors can buy shares. They have reduced the price of older warrants to as low as $0.23 or $0.58 to encourage investors to provide more cash. This shows the company is highly motivated to keep these private investors happy to stay afloat.
• Constant Selling Pressure: The company registers these shares for resale, meaning a constant supply of new stock hits the market. A large supply of shares often pushes the stock price down.

3. The "Emerging Growth" Reality

BioAffinity is an "Emerging Growth Company." This means they follow simpler rules than big companies like Pfizer. They provide less detailed financial reports, making it harder to compare their health against other businesses. They are also exempt from certain requirements, such as providing an auditor’s report on their internal financial controls.

4. What are the main risks?

Investing at this stage is high-risk. Their own filings highlight several red flags:

• Cash Flow: They are not yet profitable. They admit they must raise more cash to keep the business running. They are essentially living paycheck to paycheck through these private deals. They report recurring losses and a significant accumulated deficit.
• Operational Risks: They depend on one laboratory subsidiary, PPLS, to perform their tests. If that lab has equipment issues, faces regulatory trouble, or loses its certification, their business could stop.
• Nasdaq Listing: They warn that if they fail to meet standards—like maintaining a minimum share price—the Nasdaq could delist their stock. This would make it much harder to buy or sell shares.

5. Who is running the company?

Maria Zannes leads the company. She has a background in business and environmental law and has been the driving force in moving their technology from the lab to the market. Her team faces the difficult challenge of growing sales while managing the company’s limited cash.

How to make your next move

Before you decide to invest, take these three steps:

1. Check the SEC Filings: Look at their latest 10-Q or 10-K filings on the SEC website. Specifically, look for the "Risk Factors" section—it’s the most honest part of the document.
2. Watch the Cash: Since they aren't profitable, keep an eye on how much cash they have left. If they announce another "private placement," it usually means they are running low on money again.
3. Consider the "Dilution" Factor: Remember that every time they issue new shares to raise cash, your slice of the company gets smaller. Ask yourself if the potential growth of their technology outweighs the risk of your shares becoming less valuable over time.

Disclaimer: I am an AI, not a financial advisor. Biotech stocks are volatile. Never invest money you cannot afford to lose, and always check the latest SEC filings before making a decision. This guide is for educational purposes only.